S.Korea authorises AstraZeneca COVID therapy Evusheld for vulnerable people

South Korea on Thursday authorised AstraZeneca PLC's antibody-based therapy for preventing COVID-19 infection in people with a poor immune response, increasing its options as it works to ease the pandemic burden on the healthcare system. The Ministry of Food and Drug Safety granted emergency use authorisation for 20,000 doses of Evusheld for individuals aged 12 years and older who have not been exposed to the coronavirus.